D-Leucine-6-luteinizing hormone-releasing hormone ethylamide in the treatment of normogonadotropic oligoasthenospermia

L. Schwarzstein, N. J. Aparicio, D. Turner, E. A. De Turner, F. Premoli, Andrew V Schally

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The effectiveness of D-leucine-6-luteinizing hormone-releasing hormone ethylamide (D-Leu-6-LH-RH-EA) in the treatment of idiopathic normogonadotropic oligoasthenospermia was assessed in 17 patients selected on the basis of at least three previous sperm counts; a history of long-standing infertility; normal serum levels of luteinizing hormone, follicle-stimulating hormone, and testosterone; and lack of any evidence of other pathologic involvement. On testicular biopsy all patients showed hypospermatogenesis or arrest at the spermatid stage with the exception of two with more severe disorders. D-Leu-6- LH-RH-EA was administered intramuscularly for 90 days at a daily dose of 5 μg (four patients), 10 μg (four patients), 20 μg (five patients), and 200 μg (four patients). The results showed no significant improvement in the parameters considered (number of spermatozoa per milliliter, percentage of live and motile spermatozoa, and percentage of forwardly progressive spermatozoa). D-Leu-6-LH-RH-EA does not seem promising for the treatment of oligoasthenospermic patients.

Original languageEnglish
Pages (from-to)332-335
Number of pages4
JournalFertility and Sterility
Volume29
Issue number3
StatePublished - Jul 7 1978
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Leucine
Spermatozoa
Therapeutics
Oligospermia
Sperm Count
Spermatids
Follicle Stimulating Hormone
Luteinizing Hormone
Infertility
Testosterone
Biopsy
Serum

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

D-Leucine-6-luteinizing hormone-releasing hormone ethylamide in the treatment of normogonadotropic oligoasthenospermia. / Schwarzstein, L.; Aparicio, N. J.; Turner, D.; De Turner, E. A.; Premoli, F.; Schally, Andrew V.

In: Fertility and Sterility, Vol. 29, No. 3, 07.07.1978, p. 332-335.

Research output: Contribution to journalArticle

Schwarzstein, L, Aparicio, NJ, Turner, D, De Turner, EA, Premoli, F & Schally, AV 1978, 'D-Leucine-6-luteinizing hormone-releasing hormone ethylamide in the treatment of normogonadotropic oligoasthenospermia', Fertility and Sterility, vol. 29, no. 3, pp. 332-335.
Schwarzstein, L. ; Aparicio, N. J. ; Turner, D. ; De Turner, E. A. ; Premoli, F. ; Schally, Andrew V. / D-Leucine-6-luteinizing hormone-releasing hormone ethylamide in the treatment of normogonadotropic oligoasthenospermia. In: Fertility and Sterility. 1978 ; Vol. 29, No. 3. pp. 332-335.
@article{0c23d5d417a04e1998c7b554f945958e,
title = "D-Leucine-6-luteinizing hormone-releasing hormone ethylamide in the treatment of normogonadotropic oligoasthenospermia",
abstract = "The effectiveness of D-leucine-6-luteinizing hormone-releasing hormone ethylamide (D-Leu-6-LH-RH-EA) in the treatment of idiopathic normogonadotropic oligoasthenospermia was assessed in 17 patients selected on the basis of at least three previous sperm counts; a history of long-standing infertility; normal serum levels of luteinizing hormone, follicle-stimulating hormone, and testosterone; and lack of any evidence of other pathologic involvement. On testicular biopsy all patients showed hypospermatogenesis or arrest at the spermatid stage with the exception of two with more severe disorders. D-Leu-6- LH-RH-EA was administered intramuscularly for 90 days at a daily dose of 5 μg (four patients), 10 μg (four patients), 20 μg (five patients), and 200 μg (four patients). The results showed no significant improvement in the parameters considered (number of spermatozoa per milliliter, percentage of live and motile spermatozoa, and percentage of forwardly progressive spermatozoa). D-Leu-6-LH-RH-EA does not seem promising for the treatment of oligoasthenospermic patients.",
author = "L. Schwarzstein and Aparicio, {N. J.} and D. Turner and {De Turner}, {E. A.} and F. Premoli and Schally, {Andrew V}",
year = "1978",
month = "7",
day = "7",
language = "English",
volume = "29",
pages = "332--335",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - D-Leucine-6-luteinizing hormone-releasing hormone ethylamide in the treatment of normogonadotropic oligoasthenospermia

AU - Schwarzstein, L.

AU - Aparicio, N. J.

AU - Turner, D.

AU - De Turner, E. A.

AU - Premoli, F.

AU - Schally, Andrew V

PY - 1978/7/7

Y1 - 1978/7/7

N2 - The effectiveness of D-leucine-6-luteinizing hormone-releasing hormone ethylamide (D-Leu-6-LH-RH-EA) in the treatment of idiopathic normogonadotropic oligoasthenospermia was assessed in 17 patients selected on the basis of at least three previous sperm counts; a history of long-standing infertility; normal serum levels of luteinizing hormone, follicle-stimulating hormone, and testosterone; and lack of any evidence of other pathologic involvement. On testicular biopsy all patients showed hypospermatogenesis or arrest at the spermatid stage with the exception of two with more severe disorders. D-Leu-6- LH-RH-EA was administered intramuscularly for 90 days at a daily dose of 5 μg (four patients), 10 μg (four patients), 20 μg (five patients), and 200 μg (four patients). The results showed no significant improvement in the parameters considered (number of spermatozoa per milliliter, percentage of live and motile spermatozoa, and percentage of forwardly progressive spermatozoa). D-Leu-6-LH-RH-EA does not seem promising for the treatment of oligoasthenospermic patients.

AB - The effectiveness of D-leucine-6-luteinizing hormone-releasing hormone ethylamide (D-Leu-6-LH-RH-EA) in the treatment of idiopathic normogonadotropic oligoasthenospermia was assessed in 17 patients selected on the basis of at least three previous sperm counts; a history of long-standing infertility; normal serum levels of luteinizing hormone, follicle-stimulating hormone, and testosterone; and lack of any evidence of other pathologic involvement. On testicular biopsy all patients showed hypospermatogenesis or arrest at the spermatid stage with the exception of two with more severe disorders. D-Leu-6- LH-RH-EA was administered intramuscularly for 90 days at a daily dose of 5 μg (four patients), 10 μg (four patients), 20 μg (five patients), and 200 μg (four patients). The results showed no significant improvement in the parameters considered (number of spermatozoa per milliliter, percentage of live and motile spermatozoa, and percentage of forwardly progressive spermatozoa). D-Leu-6-LH-RH-EA does not seem promising for the treatment of oligoasthenospermic patients.

UR - http://www.scopus.com/inward/record.url?scp=0017800520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017800520&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 332

EP - 335

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 3

ER -